About Tripartite motif-containing protein 54
Tripartite motif-containing protein 54 (TRIM54) is a protein
from Homo sapiens identified by UniProt accession
Q9BYV2, 358 residues long.
MolForge cross-references it against 0 known binders and
157 disease associations.
Target properties
| Protein name | Tripartite motif-containing protein 54 |
| UniProt accession | Q9BYV2 |
| Gene | TRIM54 |
| Organism | Homo sapiens |
| Length | 358 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (157)
Diseases linked to this target (Open Targets).
- mean corpuscular hemoglobin concentration · score 0.09
- hepatocellular carcinoma · score 0.08
- hypertrophic cardiomyopathy · score 0.07
- Barrett's esophagus · score 0.06
- dilated cardiomyopathy · score 0.06
- left ventricular noncompaction · score 0.06
- neoplasm · score 0.05
- dilated cardiomyopathy 1M · score 0.05
- autosomal recessive limb-girdle muscular dystrophy type 2E · score 0.05
- Distal myotilinopathy · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9BYV2-F1 | alphafold | PREDICTED | 83.13 | — |
Amino-acid sequence (358 residues)
MNFTVGFKPL LGDAHSMDNL EKQLICPICL EMFSKPVVIL PCQHNLCRKC ANDVFQASNP LWQSRGSTTV SSGGRFRCPS CRHEVVLDRH GVYGLQRNLL VENIIDIYKQ ESSRPLHSKA EQHLMCEEHE EEKINIYCLS CEVPTCSLCK VFGAHKDCEV APLPTIYKRQ KSELSDGIAM LVAGNDRVQA VITQMEEVCQ TIEDNSRRQK QLLNQRFESL CAVLEERKGE LLQALAREQE EKLQRVRGLI RQYGDHLEAS SKLVESAIQS MEEPQMALYL QQAKELINKV GAMSKVELAG RPEPGYESME QFTVRVEHVA EMLRTIDFQP GASGEEEEVA PDGEEGSAGP EEERPDGP
Explore Tripartite motif-containing protein 54 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets